Semaglutide
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
Novo Nordisk · Phase 3 · Not yet recruiting · Enrollment 352
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Group A: Bofanglutida (GZR18), | n/r | n/r | n/r | n/r |
| Group B: Semaglutide | n/r | n/r | n/r | n/r |
Not shown
- Group A: Bofanglutida (GZR18),: endpoint not reported
- Group B: Semaglutide: endpoint not reported